Pacira BioSciences Inc (FRA:82P)
€ 20.6 +1.3 (+6.74%) Market Cap: 809.58 Mil Enterprise Value: 992.49 Mil PE Ratio: 209.12 PB Ratio: 1.50 GF Score: 74/100

Pacira Biosciences Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2026 / 06:30PM GMT
Release Date Price: €19 (-0.52%)
Jenna Davidner
Barclays Services Corp - Equity Analyst

All right. I think we're good to go. Good afternoon, everyone, and thanks for joining us at the Barclays Miami Conference. I'm joined on stage by Pacira Biosciences and representing the company is the Chief Executive Officer, Frank Lee. Thank you for being here with us today.

Questions & Answers

Jenna Davidner
Barclays Services Corp - Equity Analyst

Maybe just to kick off the conversation, if you could give us a quick overview of the current product portfolio and then maybe walk us through 2025, how things trended relative to what you expected? And maybe within that, 2025 was an important year because for your biggest product, there was the NOPAIN reimbursement implementation in January. So we'll get into some of the more financial-related questions. But with respect to NOPAIN, maybe just talk about what you've learned in the first year of having that in place?

Frank Lee
Pacira Biosciences Inc - Chief Executive Officer, Director

Well, Jenna, thanks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot